December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zealand Pharma A/S - American Depositary Shares (NQ:ZEAL)

N/A UNCHANGED
Last Price Updated: 3:24 PM EDT, Sep 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zealand Pharma A/S - American Depositary Shares

< Previous 1 2 Next >
News headline image
Zealand Pharma Hosts Conference Call on November 10 at 4pm CET (10am ET) to Present Third Quarter Results for 2022
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma Announces Presentations at The Obesity Society Annual Meeting
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma major shareholder announcement: Polar Capital
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma major shareholder announcement: Van Herk Investments
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma's Dasiglucagon Aces Late-Stage Study In Pediatric Patients, Shares Move Higher ↗
Zealand Pharma A/S (NASDAQ: ZEAL) has 
Via Benzinga
News headline image
Recap: Zealand Pharma Q1 Earnings ↗
Zealand Pharma (NASDAQ:ZEAL) reported its Q1 earnings results on Thursday, May 12, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Zealand Pharma Amends Financing Agreement With Oberland Capital ↗
 
Via Benzinga
News headline image
Zealand Pharma completes registration of capital increase
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma announces completion of a directed issue and private placement of 4,975,000 new ordinary shares raising gross proceeds of approx. DKK 786 million
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma announces directed issue and private placement of approximately 4.5m new shares
From Zealand Pharma
Via GlobeNewswire
News headline image
Novo Nordisk Touts Another Once-Weekly Insulin Icodec Win In Type 2 Diabetes ↗
 
Via Benzinga
News headline image
Recap: Zealand Pharma Q4 Earnings ↗
Zealand Pharma (NASDAQ:ZEAL) reported its Q4 earnings results on Thursday, March 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
News headline image
Total number of shares and voting rights in Zealand Pharma at September 30, 2022
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1)
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma, Novo Nordisk Ink Licensing Pact For Drug To Lower Blood Sugar Levels ↗
 
Via Benzinga
News headline image
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday ↗
Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results. 
Via Benzinga
News headline image
Why Twin Vee Powercats Is Trading Higher By Around 90%, Here Are 84 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Twin Vee Powercats Co. (NASDAQ: VEEE) shares jumped 90% to $7.60 after the company said Q2 sales results were up year over year. 
Via Benzinga
News headline image
The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
71 Biggest Movers From Yesterday ↗
Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares jumped 76.3% to close at $5.50 on Thursday after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation... 
Via Benzinga
News headline image
Mid-Afternoon Market Update: Dow Falls 150 Points; NeuroMetrix Shares Spike Higher ↗
U.S. stocks traded mixed toward the end of trading, with the Dow Jones dropping around 150 points on Thursday. 
Via Benzinga
News headline image
38 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares climbed 34.6% to $4.1993 after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for... 
Via Benzinga
News headline image
Why Zealand Pharma Shares Are Rising ↗
Zealand Pharma A/S - ADR (NASDAQ: ZEAL) shares are trading higher by 17.01% at $13.69 after the company announced the results from its phase 3 trial of Dasiglucagon in pediatric... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
On Monday, 198 companies reached new 52-week lows. 
Via Benzinga
News headline image
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Earnings Outlook For Zealand Pharma ↗
Zealand Pharma (NASDAQ:ZEAL) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that Zealand... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Earnings Scheduled For May 12, 2022 ↗
Companies Reporting Before The Bell • Chicago Atlantic Real (NASDAQ:REFI) is projected to report earnings for its first quarter. 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.